Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc.; distributor: randril international co. inc. - ibuprofen , paracetamol - tablet - 400 mg/325 mg

Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc.; importer: n/a; distributor: tgp pharma inc. - ascorbic acid , zinc , cholecalciferol (vitamin d3) - capsule - 500 mg (equivalent 562.43 mg sodium ascorbate)/ 10 mg (equivalent to 70 mg zinc gluconate)/ 1,000 iu per capsule

Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc.; importer: n/a; distributor: tgp pharma, inc. - tgp zinc gluconate - syrup (orange flavor) - 10 mg (equivalent to 70 mg zinc gluconate)/5 ml

Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc. - zinc gluconate - chewable tablet - 10 mg(equivalent to 70 mg zinc gluconate)

Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc.; distributor: n/a - zinc - film-coated tablet - 10 mg (equivalent to 27.45 mg zinc sulfate monohydrate)

Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc.; importer: n/a; distributor: n/a - zinc (as gluconate) - chewable tablet (equivalent to 70 mg zinc gluconate) - 10 mg

Israel - English - Ministry of Health

amgen europe b.v. - blinatumomab - powder for concentrate for solution for infusion - blinatumomab 35 mcg / 1 vial - blinatumomab - • blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b- precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options.• blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%.• blincyto is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b-cell precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.• blincyto is indicated as monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b precursor all as part of the consolidation therapy.limitations of use: after failure of two previous treatments and with no cns involvement.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

akzo nobel pty limited - cuprous oxide; zinc pyrithione; liquid hydrocarbon - paint - cuprous oxide mineral-copper active 660.0 g/l; zinc pyrithione mineral-zinc active 64.0 g/l; liquid hydrocarbon solvent other 515.0 g/l - antifouling - boat hull (refer to label) - marine growth | barnacles | fresh-water fouling organisms | marine fouling organisms | mussels

Australia - English - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - incobotulinumtoxina, quantity: 100 u - injection, powder for - excipient ingredients: albumin; sucrose - xeomin is indicated in adults for the treatment of:,? cervical dystonia (spasmodic torticollis),? blepharospasm,? spasticity of the upper limb,? chronic sialorrhea due to neurological disorders,? upper facial lines,- glabellar frown lines,- lateral periorbital lines (crow?s feet),- horizontal forehead lines,xeomin is indicated in children and adolescents aged 2 years to 17 years for the symptomatic treatment of:,? chronic sialorrhea due to neurological/neurodevelopmental disorders,? spasticity of the lower and/or upper limbs

Australia - English - Department of Health (Therapeutic Goods Administration)

merz australia pty ltd - incobotulinumtoxina, quantity: 50 u - injection, powder for - excipient ingredients: albumin; sucrose - xeomin is indicated in adults for the treatment of:,? cervical dystonia (spasmodic torticollis),? blepharospasm,? spasticity of the upper limb,? chronic sialorrhea due to neurological disorders,? upper facial lines,- glabellar frown lines,- lateral periorbital lines (crow?s feet),- horizontal forehead lines,xeomin is indicated in children and adolescents aged 2 years to 17 years for the symptomatic treatment of:,? chronic sialorrhea due to neurological/neurodevelopmental disorders,? spasticity of the lower and/or upper limbs